But today’s deal with Jiangsu Hengrui doesn’t mean that the group is turning away from an earlier tie-up with Nerviano.

The presidential session heralds a combo of Padcev and Keytruda as the new front-line bladder cancer standard of care.

Novartis looks set to hand nisevokitug rights back to Xoma, though plenty of work on TGF-β continues.